Advancing Genetic Treatments Against Blindness
GenSight Biologics is an early clinical-stage biopharmaceutical company pioneering the development of gene therapy based solutions to preserve or restore vision in people with degenerative retinal and inherited ophthalmologic diseases
Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to (i) prevent retinal degeneration in selected pathological conditions and (ii) to restore vision in patients suffering from very low vision or blindness.
Founded in 2012, the company is building on its close relationship with José Sahel, Botond Roska, Ernst Bamberg, Jean Bennett, Luk Vandenberghe and Connie Cepko, six of the world’s most renowned leading experts in this field and co-founders of GenSight Biologics.
Our strategic vision is to become the leader in gene therapy for ophthalmology diseases. We aim to develop, on the basis of our technology and know-how in the field of AAV vectors, optogenetics and genetic disorders, innovative therapeutic products that could avoid sight loss or restore vision in patients suffering from various forms of retinal degeneration.
Vision loss is the most feared consequence of disease apart from death. There are 15 million people in the Western world suffering from blindness or very limited vision, with few, if any treatments. Very limited vision and blindness are associated with very high costs (current estimates are more than €200 billion in the EU alone).
June 23-26, 2014: GenSight Biologics attended BIO, San Diego, CA, USA
June 6, 2014: GenSight Biologics win the award of the Investor Conference at BioVision Investor Conference, Lyon, France
Read the full press release (in French)
May 21-22, 2014: GenSight Biologics presented in the the Next wave Companies list at BioEquity, Amsterdam, the Netherlands
May 4-9, 2014: GenSight Biologics attended ARVO annual meeting, Orlando, FL, USA and presented a poster
Title: Safety, local tolerability and biodistribution of GS010 (AAV2/2-ND4), a gene therapy medicinal product in development for Leber Hereditary Optic Neuropathy (LHON)
May 6, 2014 from 11:00 AM to 12:45 PM, Physiology/Pharmacology, 342 Gene Therapy and Delivery, Poster Number: 3340 - B0280
March 10-12, 2014: GenSight Biologics presented at BioEurope Spring
February 28, 2014: GenSight Biologics expands its Series A round to the French seed fund for innovative biotherapies and rare diseases
In 2013, the company raised a total € 35 M Series A financing from European blue-chip capital firms (Abingworth LLP, Novartis Venture Fund, Versant Ventures and Index Ventures) and the French Rare Diseases seed Fund, to develop a first replacement therapy of a gene responsible for vision loss in LHON, currently in phase I and a second approach based on optogenetics, to restore vision in patients with very low vision or total blindness due to RP. Read the full press release (available only in French)
January 13-16, 2014: GenSight Biologics attended JP Morgan Healthcare Conference and Biotech Showcase, San Francisco, CA, USA
5th Annual world Orphan Drug, Congress Europe 2014, November 12-14, 2014, Brussels, Belgium
AAO, October 18 - 21, 2014, McCormick Place, Chicago (IL)
J.P.Morgan 33rd Annual Healthcare Conference, January 12-16, 2015, San Francisco (CA)
MAJOR NEWS in 2013
October 2, 2013: GenSight, EuropaBio's Top 5 most innovative European biotech in 2013
Entering its 4th year, the EuropaBio Most Innovative EU Biotech SME Award 2013 selected top 5 candidates from which Gensight belongs to. The award has grown rapidly each year to reach a wider audience across members states, with applications coming from all three sectors of biotechnology - healthcare, industrial and agricultural, all providing solutions to major societal unmet needs. This year, the award was presented during the first ever European Biotechnology Week, at an event in Brussels which discussed Europe’s role in the booming biotech sector, in comparison with global trends. Learn more
April 9, 2013: GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy
The financing was co-led by Novartis Venture Fund, Abingworth LLP, Versant Ventures and Index Ventures. GenSight will use the funds to develop a gene replacement therapy for Leber’s hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP). Learn more